Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women

Neurology

Volumn 60, Issue 10, 2003, Pages 1591-1597

  Kang, Jae Hee ^a,c   Grodstein, Francine ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; AGING; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0038813958     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000065980.33594.b7     Document Type: Article

References (30)

1. Medical Research Council Cognitive Function and Ageing Study Writing Committee. Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. Int J Epidemiol 2001;30:1383-1388.
2. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205.
3. Linn R, Wolf PA, Bachman D, et al. The 'preclinical phase' of probable Alzheimer's disease: a 13-year prospective study of the Framingham cohort. Arch Neurol 1995;52:485-490.
4. Schneider EP. The aging of America: impact on health care costs. JAMA 1990;263:2335-2340.
5. Helling DK, Lemke JH, Semla TP, Wallace RB, Lipson DP, Cornoni-Huntley J. Medication use characteristics in the elderly: the Iowa 65+ Rural Health Study. J Am Geriatr Soc 1987;35:4-12.
6. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985;28:686-692.
7. Zandi PP, Breitner JCS. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001;22:811-817.
8. Fourrier A, Letenneur L, Begaud B, Dartigues JF. Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996;49:1201.
9. Hanlon JT, Schmader KE, Landerman LR, et al. Relation of prescription nonsteroidal anti-inflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol 1997;7:87-94.
10. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE. Aspirin, anti-inflammatory drugs and risk of dementia. In J Geriatr Psychiatry 1997;12:926-930.
11. May FE, Moore MT, Stewart RB, Hale WE. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly. Gerontology 1992;38:275-279.
12. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? Neurology 1997;50:374-379.
13. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-1029.
14. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22:2142-2147.
15. Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH. Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;143:683-691.
16. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry 1997;62:269-272.
17. Peacock JM, Folsom AR, Knopman DS, Mosley TH, Goff DC, Szklo M. Association of nonsteroidal anti-inflammatory drugs and aspirin with cognitive performance in middle-aged adults. Neuroepidemiology 1999; 18:134-143.
18. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-117.
19. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 1991; 57:167-178.
20. Welsh KA, Butters N, Mohs RC. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology 1994;44:609-614.
21. Roccaforte WH, Burke WJ, Bayer BL, Wengel SP. Validation of a telephone version of the Mini-Mental State Examination. J Am Geriatr Soc 1992;40:697-702.
22. Kawas C, Karagiozis H, Resau L, Corrada M, Brookmeyer R. Reliability of the Blessed Telephone Information-Memory-Concentration Test. J Geriatr Psychiatry Neurol 1995;8:238-242.
23. Evans DA, Beckett LA, Albert MS, et al. Level of education and change in cognitive function in a community population of older persons. Ann Epidemiol 1993;3:71-77.
24. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414:212-216.
25. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: The Cache County Study. Neurology 2001;57:2210-2216.
26. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer's disease. Arch Neurol 2001;58:1790-1792.
27. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
28. Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000;289:201-204.
29. Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? Stroke 1996;27:756-760.
30. Zandi PP, Anthony JC, Hayden KM, Mehta KM, Mayer L, Breitner JCS. Reduced incidence of AD with NSAID but not H2 receptor antagonists. Neurology 2002;59:880-886.